Keywords: Biotie Theapeis, Newon, M&A, D&D pipelines, Edison Research
Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research
Article | 16 October 2011
Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian biotech company Newron Pharmaceuticals (SIX: NWRN) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
